Imexpharm

Imexpharm Debt/EBITDA

The Total Debt to EBITDA Ratio of Imexpharm (IMP.VN) as of Oct 27, 2026 is 0.45. In the previous year, Total Debt to EBITDA Ratio was 0.20 — a change of 122.39% (higher).

Debt/EBITDA

0.45

YoY

122.39%

Last updated:

Total Debt to EBITDA Ratio of Imexpharm is 2025 0.45 . Total Debt to EBITDA Ratio of Imexpharm was 2024 0.20 . It decreases by 122.39% higher compared to the previous year.

The Imexpharm Debt/EBITDA history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Debt/EBITDA
Date
Debt/EBITDA
Jan 1, 2018
0.00 VND
Jan 1, 2019
0.18 VND
Jan 1, 2020
0.48 VND
Jan 1, 2021
1.02 VND
Jan 1, 2022
0.31 VND
Jan 1, 2023
0.13 VND
Jan 1, 2024
0.20 VND
Jan 1, 2025
0.45 VND
The Imexpharm Debt/EBITDA history
YEARDebt/EBITDAYoY
0.45+122.39%
0.20+60.66%
0.13-59.22%
0.31-69.75%
1.02+113.14%
0.48+172.76%
0.18—
0.00—
0.00—
0.00—
0.00—
0.00—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Imexpharm Stock analysis

What does Imexpharm do? Imexpharm Corp manufactures and trades pharmaceuticals, medicinal chemicals, and botanical products, including antiseptics, traditional medicine, medical equipment, cosmetics, and supplemental food and drinks. The company provides packaging and warehousing services specifically for pharmaceutical storage. It also cultivates medicinal herbs. Imexpharm Corp serves the pharmaceutical industry and healthcare sector through its manufacturing, import, export, and trade operations, targeting businesses requiring medicinal products and services. The company's revenue streams include the sale of manufactured pharmaceuticals, imported and exported goods, and services such as packaging and warehousing. Its customers are businesses in the healthcare sector, including distributors and retailers of pharmaceuticals, medical equipment, and related products. The firm's operations span manufacturing, import, export, and trade, with additional services supporting the pharmaceutical supply chain. Imexpharm Corp's product portfolio covers a wide range of medicinal and health-related items, from antiseptics to supplemental food and drinks. The company's involvement in medicinal herb cultivation supports its production of traditional medicine and herbal-based products. This vertical integration enhances its ability to supply comprehensive solutions to healthcare businesses. Imexpharm is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Imexpharm stock

Total Debt to EBITDA Ratio of Imexpharm is 0.45 in 2025.

Total Debt to EBITDA Ratio of Imexpharm changed from 0.20 to 0.45, representing a 122.39% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Total Debt to EBITDA Ratio Imexpharm since 2006 – with annual values, charts, and detailed analysis.

Debt/EBITDA measures total debt relative to earnings before interest, taxes, depreciation, and amortization. It indicates the years needed to repay all debt from EBITDA.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Total Debt to EBITDA Ratio's Imexpharm with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Leverage — Imexpharm

All Key Metrics — Imexpharm